| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE39071 | CUBIST PHARMS LLC | Anhydro-and isomer-a-21978c cyclic peptides |
Jun, 2016
(7 years ago) | |
| US8058238 | CUBIST PHARMS LLC | High purity lipopeptides |
Nov, 2020
(3 years ago) | |
| US8129342 | CUBIST PHARMS LLC | High purity lipopeptides |
Nov, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6852689 | CUBIST PHARMS LLC | Methods for administration of antibiotics |
Sep, 2019
(4 years ago) | |
| US6468967 | CUBIST PHARMS LLC | Methods for administration of antibiotics |
Sep, 2019
(4 years ago) | |
| US8003673 | CUBIST PHARMS LLC | Daptomycin for the treatment of biofilm and catheter salvage |
Sep, 2028
(4 years from now) | |
| US9138456 | CUBIST PHARMS LLC | Lipopeptide compositions and related methods |
Nov, 2030
(6 years from now) | |
Cubicin is owned by Cubist Pharms Llc.
Cubicin contains Daptomycin.
Cubicin has a total of 7 drug patents out of which 5 drug patents have expired.
Expired drug patents of Cubicin are:
- US6852689
- US6468967
- USRE39071
- US8058238
- US8129342
Cubicin was authorised for market use on 12 September, 2003.
Cubicin is available in powder;intravenous dosage forms.
Cubicin can be used as method for treating bacterial infection, treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided infective endocarditis, method of treating bacterial infections.
The generics of Cubicin are possible to be released after 23 November, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-211) | Sep 01, 2020 |
| New Patient Population(NPP) | Mar 29, 2020 |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 12 September, 2003
Treatment: Method of treating bacterial infections; Treatment of the following infections: complicated skin and skin structure infections and staphylococcus aureus bloodstream infections (bacteremia) including t...
Dosage: POWDER;INTRAVENOUS
CUBICIN family patents
